CVS Health Corp. CVS

NYSE · Healthcare · Medical - Healthcare Plans

$80.84

Close on Fri, 20 Nov 2026 · market value $103B

What the price is betting on

Below its record

At $81, the price assumes revenue shrinks about 19% a year for five years, from $421B to about $176B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes−19%
Analysts, next two years3.1%
Last 3 years6.1%

Revenue growth a year. The price figure comes from a reverse DCF at a 7.6% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than CVS? Check up to 5 of your stocks at once, free, no account.

0$200B$400B$600B$421B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$253

Base

$284

Bull

$317

Today $81

  • Bear $253. Cash flow grows 2% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $284. Cash flow grows 4% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $317. Cash flow grows 6% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$399B$422B, on the path
  3. FY2027$325B$433B, on the path
  4. FY2028$265B$452B, on the path
  5. FY2029$216B$483B, on the path
  6. FY2030$176B$502B, on the path

Each year's revenue at −19% growth from $421B in the 12 months to September 2026.

At a glance

Healthcare · Medical - Healthcare Plans · listed on NYSE

Revenue, FY2025
$402B
Growth, 3 years a year
6.1%
Cash margin
1.9%
Net debt
$69.4B
Shares, 3-year change
−3.9%
Dividend yield
3.3%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.